Making Time—A Meta-Static Journey

JAMA Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

This essay describes the author’s experience with an unexpected diagnosis of stage IV cancer and valuable perspectives gained from additional quality time.

Language: Английский

---

Pharmacologic Treatment and Management of Coronavirus Disease 2019

Infectious Disease Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Real-World Experience with the Available Outpatient COVID-19 THErapies in Patients with canceR (CO.THER)

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 999 - 999

Published: March 17, 2025

Background/Objectives: Cancer represents an important risk factor for acquiring severe acute respiratory syndrome by Coronavirus-2 (SARS-CoV-2) and subsequent hospitalization. The utility of early antiviral therapies, including their protective effect on long COVID outcomes, in cancer patients has not yet been clearly demonstrated. We conducted the CO.THER study (COVID-19 THErapies with canceR) to address this knowledge gap. Methods: designed ambispective single-center cohort study. collected clinical oncological data from hospital’s electronic patient records at start COVID-19 therapy (T0), seven days after T0 (T1), two weeks (T2), one month (T3), three months (T4), six (T5), twelve (T6). primary endpoint was rate hospitalization disease within 14 using anti-SARS-CoV-2 therapies. proportion hospitalizations (primary endpoint) computed together its exact binomial 95% confidence interval (95%CI). Results: 131 patients’ (53M [40.5%], 78F, [59.5%]; median age 62.45, interquartile range [IQR] 56–71) were enrolled. As shown Kaplan–Meier hospitalization-free estimate, only (2.1%) hospitalized a related cause starting treatment (95%CI 0.5–6.6%). cumulative survival probability beyond 12 98% 93–99%). Twelve (9.2%) reported another infection during follow-up they all retreated Nirmatrelvir–Ritonavir. reinfection-free 90% 83–95%). Further, 15 123 evaluable 3 (median 51 years, IQR 40–68) symptoms (12.2%, 95%CI 7.0–19.3%). Conclusions: Our demonstrate low reassuring safety high-risk subjects.

Language: Английский

---

Oral antivirals for COVID-19 among patients with cancer: correspondence

Supportive Care in Cancer, Journal Year: 2024, Volume and Issue: 32(9)

Published: Aug. 23, 2024

Language: Английский

---